Congenital sucrase-isomaltase deficiency (CSID)
What the FAA's documents say about congenital sucrase-isomaltase deficiency (CSID), in plain words, with the FAA's own words one press away.
Covers: All classes
Show the FAA's words: which classes the FAA's table covers
CONGENITAL SUCRASE-ISOMALTASE DEFICIENCY (CSID) All Classes
Short version
The disposition table has two rows.
| Situation | What the examiner does | Pathway |
|---|---|---|
| Row AWell-controlled, and no medication side effects | Examiner issues | Examiner can issue |
| Row BWith severe complications | Defers to the FAA | Special Issuance |
Show the FAA's words: the FAA's table for Congenital sucrase-isomaltase deficiency (CSID)
- Row A · Examiner can issue
Well-controlled, and no medication side effects. The table says ISSUE if the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, and verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid). The examiner summarizes findings in Item 60.
A. Well-controlled AND No medication side effects If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties AND Verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid): ISSUE Summarize findings in Item 60.
- Row B · Special Issuance
CSID with severe complications. The table lists what to submit for FAA review. The examiner defers, submits the information to the FAA for a possible Special Issuance, and summarizes findings in Item 60.
B. With severe complications Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance. Summarize findings in Item 60.
The FAA pathways for congenital sucrase-isomaltase deficiency (CSID)
Which one describes yours?
The FAA's table sorts it these ways. Choose yours to see its plan.
Your step-by-step plan
Step 1: Row A: what the examiner determines
Well-controlled, and no medication side effects.For Row A, your AME determines the things the table lists and verifies the waiting period. If your AME can, the table says ISSUE.
If the AME can determine
- The condition is under control
- Current medications are acceptable
- No symptoms that would interfere with flight or safety related duties
And verifies
- A 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid)
At the exam
- Your AME summarizes findings in Item 60
Show the FAA's words: Row A: what the examiner determines
If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties AND Verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid):
ISSUE
FAA source: Congenital Sucrase Isomaltase Deficiency CSID. FAA date 26 August 2026; checked by Crosscheck 14 October 2026.
ISSUE Summarize findings in Item 60.
FAA source: Congenital Sucrase Isomaltase Deficiency CSID. FAA date 26 August 2026; checked by Crosscheck 14 October 2026.
Step 2: See your AME
The table says ISSUE if the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, and verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid). The examiner summarizes findings in Item 60.Exam day- The table says ISSUE if the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, and verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid). The examiner summarizes findings in Item 60.
Show the FAA's words: See your AME
A. Well-controlled AND No medication side effects If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties AND Verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid): ISSUE Summarize findings in Item 60.
FAA source: Congenital Sucrase Isomaltase Deficiency CSID. FAA date 26 August 2026; checked by Crosscheck 14 October 2026.
What the examiner checks
It depends on which row of the FAA's table describes the case.
Row AExaminer issuesExaminer can issue
The table says ISSUE if the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, and verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid). The examiner summarizes findings in Item 60.
Row BDefers to the FAASpecial Issuance
The table lists what to submit for FAA review. The examiner defers, submits the information to the FAA for a possible Special Issuance, and summarizes findings in Item 60.
If the examiner defers
Show the FAA's words: what the examiner does on each row
- Row A · Examiner can issue
Well-controlled, and no medication side effects. The table says ISSUE if the examiner can determine the condition is under control, current medications are acceptable, and there are no symptoms that would interfere with flight or safety related duties, and verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid). The examiner summarizes findings in Item 60.
A. Well-controlled AND No medication side effects If the AME can determine the condition is under control, current medications are acceptable, and no symptoms that would interfere with flight or safety related duties AND Verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid): ISSUE Summarize findings in Item 60.
- Row B · Special Issuance
CSID with severe complications. The table lists what to submit for FAA review. The examiner defers, submits the information to the FAA for a possible Special Issuance, and summarizes findings in Item 60.
B. With severe complications Submit the following for FAA review: … DEFER Submit the information to the FAA for a possible Special Issuance. Summarize findings in Item 60.
If the examiner defersSpecial Issuance
The table marks Row B, with severe complications, DEFER.
What the FAA lists to send
- Item 1. A current, detailed clinical progress note generated from a clinic visit with the treating physician no more than 90 days before the exam, with what the table says it should include.
- Item 2. The results of any other testing already performed by the treating physician.
Show the FAA's words: if the examiner defers
When the examiner defers
- Reason 1
The table marks Row B, with severe complications, DEFER.
B. With severe complications … DEFER Submit the information to the FAA for a possible Special Issuance.
What the FAA lists to send
- Item 1
A current, detailed clinical progress note generated from a clinic visit with the treating physician no more than 90 days before the exam, with what the table says it should include.
1. A current, detailed Clinical Progress Note generated from a clinic visit with the treating physician no more than 90 days before the AME exam. It should include
- Item 2
The results of any other testing already performed by the treating physician.
2. Results of any other testing already performed by the treating physician.
What a Special Issuance is
The Guide says an Authorization for Special Issuance, valid for a specified period, may be granted at the Federal Air Surgeon's discretion to a person who does not meet the established medical standards, if the person shows to the satisfaction of the Federal Air Surgeon that the duties authorized by the class of certificate applied for can be performed without endangering public safety during the period the Authorization would be in force.
How the FAA pathways workGood to know
Points from the FAA's own documents that are easy to miss.
What a progress note must include
In most cases it should come from a visit with the treating physician no more than 90 days ago, and cover the history, medications with dosages and side effects, exam findings, test results, diagnosis, assessment and plan, prognosis and follow-up. The FAA's sheet says to make sure the physician adds the prognosis. A portal note or an After Visit Summary that does not meet these criteria is not enough, and neither is a simple "ok to fly" letter. The FAA's documents also call it a status report.
Show the FAA's words: good to know, 1
your patient portal to print out “notes” or an “After Visit Summary (AVS).” … Patient Portal notes or an AVS that do not meet the criteria listed below for a detailed Clinical Progress Note are NOT sufficient for FAA purposes. … To be “current,” in MOST CASES, the detailed Clinical Progress Note should be from an evaluation in which you saw your treating physician no more than 90 days ago. … It Must include the following items: … A summary of the history of the condition, … Current medications, dosages, and side effects (if any); … Clinical exam findings; … Results of any testing performed; … Diagnosis; … Assessment and Plan; … Prognosis (This item may not be on a standard progress note, make sure your physician adds this information.); and … Follow-up … Please note: A letter stating, “Mr. Smith is ok to fly” (or any other simple note), is NOT a current, detailed Clinical Progress Note and is NOT acceptable. … You may also see this called a “current status report” or “status report” in current FAA Guidance. Any reference to a “status report” equals the criteria listed on this sheet.
A 7-day waiting period after starting sacrosidase
Row A's ISSUE includes that the examiner verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid). The row does not say what applies where sacrosidase has not been started.
Show the FAA's words: good to know, 2
AND Verifies a 7-day waiting period has elapsed since starting medication sacrosidase (Sucraid): … ISSUE
Severe complications are Row B
Row B is CSID with severe complications, and the table marks it DEFER. The table does not say what makes a complication severe.
Show the FAA's words: good to know, 3
B. With severe complications … DEFER Submit the information to the FAA for a possible Special Issuance.
FAA sources
Every FAA document this page relies on, with the FAA's own date and the date Crosscheck last read it. The documents to print open at the FAA, so they are always the FAA's current ones.
This reports what the FAA has published. It is not medical advice, and it does not say how the FAA or an examiner will decide a case.